Sanofi’s (SNY) Neutral Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of Sanofi (NASDAQ:SNY) in a research report report published on Monday morning, Marketbeat Ratings reports.

A number of other brokerages also recently issued reports on SNY. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Sanofi in a research report on Monday, December 1st. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Stock Up 0.9%

Shares of SNY opened at $48.26 on Monday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock has a market capitalization of $118.50 billion, a price-to-earnings ratio of 11.30, a PEG ratio of 1.30 and a beta of 0.44. The stock has a 50 day moving average price of $49.94 and a 200 day moving average price of $49.09. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the prior year, the business earned $2.25 earnings per share. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several hedge funds have recently made changes to their positions in the business. Financial Consulate Inc. acquired a new stake in Sanofi during the 3rd quarter worth approximately $26,000. Ameritas Advisory Services LLC purchased a new position in Sanofi during the second quarter worth about $28,000. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi in the third quarter valued at about $29,000. Palisade Asset Management LLC purchased a new stake in Sanofi in the 3rd quarter valued at approximately $30,000. Finally, Banque Transatlantique SA purchased a new stake in Sanofi in the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.